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Abstract
Clinical trials have confirmed the safety of selectively oncolytic adenoviruses for treatment of advanced cancers. However,
increasingly effective viruses could result in more toxicity and therefore it would be useful if replication could be abrogated
if necessary. We analyzed viruses containing the cyclooxygenase-2 (Cox-2) or vascular endothelial growth factor (VEGF)
promoter for controlling replication. Anti-inflammatory agents can lower Cox-2 protein levels and therefore we
hypothesized that also the promoter might be affected. As Cox-2 modulates expression of VEGF, also the VEGF promoter
might be controllable. First, we evaluated the effect of anti-inflammatory agents on promoter activity or adenovirus
infectivity in vitro. Further, we analyzed the oncolytic potency of the viruses in vitro and in vivo with and without the
reagents. Moreover, the effect of on virus replication was analyzed. We found that RGD-4C or Ad5/3 modified fibers
improved the oncolytic potency of the viruses in vitro and in vivo. We found that both promoters could be downregulated
with dexamethasone, sodium salicylate, or salicylic acid. Oncolytic efficacy correlated with the promoter activity and in vitro
virus production could be abrogated with the substances. In vivo, we saw good therapeutic efficacy of the viruses in a
model of intravenous therapy of metastatic cervical cancer, but the inhibitory effect of dexamethasone was not strong
enough to provide significant differences in a complex in vivo environment. Our results suggest that anti-inflammatory
drugs may affect the replication of adenovirus, which might be relevant in case of replication associated side effects.
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Introduction
The pathogenesis of cervical cancer is characterized by
persistent infection with a high-risk human papillomavirus
(HPV), generally accepted as required for cervical cancer
initiation. In a fraction of patients, HPV infection progresses from
dysplasia and carcinoma in situ to invasive cancer and metastatic
disease [1]. Only a few viral strains are specifically responsible for
cervical neoplasms, of which HPV16 accounts for more than one-
half of reported cases. Unfortunately, neither improvements in
surgery nor radiotherapy have significantly decreased mortality of
patients with advanced, recurrent, or metastatic disease. The
American Cancer Society estimates about 9 700 new cases and
3 700 deaths in cervical cancer in 2006 [2]. However, cervical
cancer remains the leading cause of gynecological cancer mortality
worldwide with over 270 000 deaths in 2002 [3].
Adenoviral gene therapy has been proposed as a novel
treatment alternative for advanced cancer [4]. However, effective
tumor transduction continues to be the limiting step for achieving
clinical results. Oncolytic adenoviruses might prove useful in this
regard [5]. These viruses have a cytolytic nature, i.e. the replicative
life cycle of the virus results in host cell destruction. Modifications
in the viral genome reduce replication in normal tissues, while
tumor cells continue to allow productive replication leading to
cancer cell lysis (oncolysis). Type I oncolytic adenoviruses feature
loss-of-function mutations in the virus genome, which are
compensated by mutations in cancer but not normal cells. This
can be achieved by incorporating deletions in the early adenoviral
genes resulting in mutant E1 proteins unable to bind cellular
proteins necessary for viral replication in normal cells, but not in
cancer cells. In type II viruses, tumor or tissue specific promoters
replace endogenous viral promoters such as the E1A promoter, to
restrict viral replication to target tissues expressing the promoter.
Although clinical trials have confirmed the safety of oncolytic
adenoviruses for treatment of advanced cancers [6–9], most trials
have featured relatively attenuated viruses. Thus, increasingly
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effective agents could result in more toxicity and therefore it would
be useful if replication could be abrogated if necessary. Gene
expression from certain promoters can be regulated. For example,
the early growth response gene 1 (egr-1) enhancer/promoter, has
been used as a regulatable promoter for specific expression of
HSV-TK in glioma cells and can be induced by radiation [10].
Another regulation strategy is the use of hypoxia-inducible
promoters [11]. Further, regulation can be achieved with
chemically inducible promoters. For example, a tetracycline-
activated promoter can be used to regulate gene expression and
subsequent protein production by oral tetracycline. Withdrawal of
the drug rapidly abrogates gene expression [12].
Cox-2 is the rate-limiting enzyme in prostaglandin synthesis, and it
is involved in the control of inflammatory reactions in response to
injury or infection. Use of non-steroidal anti-inflammatory drugs
(NSAIDs) has indicated that the activity and also level of the Cox-2
protein can be regulated. Although other factors besides promoter
activity often have a role in protein expression levels, studies have
shown that activity of the Cox-2 promoter correlates well with protein
expression [13]. Further, the activity of the Cox-2 promoter in most
healthy normal tissues is low, unless it is induced by growth factors
(such as VEGF), cytokines or tumor specific factors [14]. With regard
to adenoviruses, the most relevant organ for toxicity is the liver.
Therefore, it is useful that hepatic expression of Cox-2 is low [15,16].
Cox-2 may have a role in the carcinogenesis of many epithelial
cancers, and expression levels have been linked to tumor invasiveness
and angiogenesis [14]. These reasons have led to utilization of the
Cox-2 promoter as a tumor specific promoter for cancer specific
expression [15–20].
VEGF has an important role in the induction of tumor-
associated angiogenesis, as it is a mediator of endothelial cell
proliferation, differentiation, and vascular permeability [21].
VEGF is widely expressed during tumorigenesis and it is detected
in most malignant epithelial tumors [18,19,21] Cox-2 or growth
factors like TGF-b1 can regulate VEGF [22,23]. Further, bulky
solid tumor masses contain hypoxic areas, which feature high
levels of the HIF-1 transcription factor, which in turn induces
VEGF and Cox-2 expression [23]. Thus, the regulation and
expression of Cox-2 and VEGF are linked. Consequently, it is not
completely surprising that also the VEGF promoter has shown
utility for tumor specific expression [18,19,24]. A heretofore
unexplored possibility is regulation of the Cox-2 and VEGF
promoters by anti-inflammatory agents. This might offer a safety
switch in case of promoter mediated side effects in clinical trials.
Clinical cervical cancer samples express high levels of Cox-2,
while it is undetectable in the normal epithelial lining of the cervix.
Further, there is a progressive increase in Cox-2 levels depending
on disease stage, and also tumor size. Cox-2 expression is also a
negative predictive factor for survival [25,26]. With regard to
VEGF and cervical cancer, a high pretreatment level has been
found to associate with large tumors, stromal invasion and pelvic
lymph node metastasis. VEGF expression also correlates with poor
prognosis [27–29]. Therefore, both promoters are appealing
candidates for cervical cancer specific gene therapy approaches.
Sodium salicylate and salicylic acid are NSAIDs, which
enzymatically inhibit Cox-2. Further, it has been reported that
these substances decrease Cox-2 mRNA levels, which could be
mediated through modulation of promoter activity [13,30].
Dexamethasone is an anti-inflammatory steroid which inhibits
expression of both Cox-2 mRNA and protein [30]. Further, post-
transcriptional mRNA destabilization may be an important
mechanism in the action of dexamethasone [31]. TGF-b1 is a
peptide growth factor and anti-inflammatory cytokine, which is
produced by many cells, but is found most concentrated in
mammalian platelets. It can modulate by for instance cell
proliferation and differentiation, angiogenesis and metastasis,
and has been shown to have an effect on Cox-2 levels [32].
We hypothesized that it may be possible to reduce adenovirus
replication with pharmacological intervention. Specifically, we
analyzed oncolytic viruses containing the cyclooxygenase-2 (Cox-
2) or the vascular endothelial growth factor (VEGF) promoter
controlling expression of E1A, and evaluated the effect of anti-
inflammatory reagents [sodium salicylate, dexamethasone, salicylic
acid and transforming growth factor-b1 (TGF-b1)] on oncolysis
and replication in vitro and in vivo efficacy. As controls, we included
a Retinoblastoma (Rb)-p16 pathway selective D24-based type I
oncolytic virus [33] and a wild type adenovirus. Further, as it has
become evident that a major determinant of the efficacy of
replicating adenoviruses is gene delivery efficacy [34], we utilized
fiber modified, infectivity enhanced viruses.
Results
Infectivity of human cervical cancer cell lines in vitro
Cervical cancer cell lines C33A, SiHa, Caski and HeLa were
infected with isogenic luciferase expressing viruses featuring either
the adenovirus serotype 5 capsid (Ad5luc1), a chimeric capsid with
the knob domain from serotype 3 (Ad5/3luc1) or the RGD-4C
capsid modification (Ad5lucRGD). In three out of four cell lines,
infection with Ad5/3luc1 resulted in 6 to 14-fold higher luciferase
expression in comparison to Ad5luc1 (5 000 viral particle (vp)/cell,
Fig. 1b–d). However, with C33A cells, which feature high
expression of the coxsackie-adenovirus receptor [19,35], Ad5luc1
was most effective (7-fold, Fig. 1a). Ad5lucRGD did not increase
the infectivity of cervical cancer cells in vitro, except in SiHa cells
(2.5 to 5.5-fold enhancement, Fig. 1b).
The effect of anti-inflammatory reagents on transduction
efficacy of capsid modified adenoviruses
Cervical cancer cell lines were infected with capsid modified
adenoviruses in the presence of substances. As shown in Fig. 1e–h,
dexamethasone increased the transduction efficacy with all the
viruses on SiHa and Caski cell lines. Other analyzed substances
had only minor effect.
Regulation of Cox-2 and VEGF promoters with anti-
inflammatory reagents
The transcriptional activity of the Cox-2 and VEGF promoters
was evaluated in cervical cancer cell lines with and without anti-
inflammatory reagents sodium salicylate, dexamethasone, salicylic
acid and TGF-b1 (Fig. 2a–h). Ad5luc1, which contains a very strong
CMV promoter, was used for comparison, and relative luciferase
activities are shown. Overall, the VEGF promoter induced a higher
level of transgene expression than Cox-2 (Fig. 2b, d, f, h). Promoter
expression was well in accord with previous data on Cox-2 and
VEGF mRNA expression in these cell lines [19]. Although both
promoters could be downregulated with anti-inflammatory sub-
stances, VEGF was more regularly affected (Fig. 2b, d).
Oncolytic adenoviruses displayed efficient killing of
cervical cancer cells in vitro
Monolayers of cervical cancer cells were infected with oncolytic
adenoviruses, wild-type virus and Ad5luc1, an E1-deleted control
virus (Fig. 3a–d). In all cell lines, the quantitative cell killing assay
showed cytolysis with oncolytic viruses and wild-type virus, while
Ad5luc1 caused minimal cell killing. On most cell lines, oncolysis
was significantly improved with replicating viruses in comparison
Oncolytic Adenoviruses
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to Ad5luc1. Further, oncolysis caused by RGDCRADcox-2R was
significant also on C33A and Caski cells when dose of 10 vp/cell
was used (Fig. 3a, c). On all cell lines, cell killing with Ad5-
D24RGD was comparable to wild-type adenovirus, while the
efficacy of RGDCRADcox-2R and Ad5/3VEGF-E1 was weaker.
Oncolytic adenoviruses delivered therapeutic efficacy in
murine cervical cancer models in vivo
Advanced subcutaneous C33A tumors were treated with three
intratumoral injections of 16109 vp of Ad5luc1, wild-type virus,
Ad5/3VEGF-E1, RGDCRADcox-2R or Ad5-D24RGD on three
consecutive days, or with a single intravenous injection of
161011 vp of the same viruses. Treatment with oncolytic viruses
gave significant therapeutic efficacy in both models (Fig. 3e, f:
P,0.0001 for RGDCRADcox-2R, Ad5/3VEGF-E1 or Ad5-
D24RGD versus Ad5luc1). Wild-type adenovirus did not display
a significant effect on tumor growth (P=0.1471 and 0.8297 versus
Ad5luc1 for intratumoral and intravenous models, respectively).
Anti-inflammatory reagents reduced oncolysis caused by
Cox-2 and VEGF promoter driven oncolytic adenoviruses
and wild-type adenovirus
The effect of anti-inflammatory agents on oncolytic adenovi-
ruses and wild-type virus was analyzed on C33A and SiHa cell
monolayers. None of the analyzed reagents (dexamethasone,
salicylic acid and sodium salicylate) caused significant cell killing
on their own or in combination with replication deficient E1-
deleted Ad5luc1 (Fig. 4a, e). The cell killing efficacy of replicating
viruses was reduced with dexamethasone (Fig. 4b, c, f–h), salicylic
acid (Fig. 4c) and sodium salicylate (Fig. 4f, g).
The in vivo effect of dexamethasone on therapeutic
efficacy of oncolytic or wild-type adenoviruses
Subcutaneous C33A cervical cancer tumors were allowed to
develop and the mice were treated with a single intravenous
injection of 161011 vp of Ad5/3VEGF-E1, Ad5-D24RGD or no
virus. In the RGDCRADcox-2R groups, 36108 vp were injected
intratumorally on days 1, 3 and 5. Then the mice were randomized
to intraperitoneal dexamethasone or PBS treatment (Fig. 4i). Ad5-
D24RGD was used as a model of an oncolytic virus without a tissue
specific promoter. Wild type virus could not be used because it did
not yield any efficacy in the model (Fig. 3). Despite some promising
albeit minor trends, dexamethasone did not affect tumor growth
significantly (P= from 0.5726 to 0.9909 versus virus only). However,
all oncolytic adenoviruses continued to display anti-tumor efficacy
as in the previous experiment (all P,0.0001 versus mock).
To see if we could tease out the replication attenuating effect of
dexamethasone in a fast growing, highly aggressive subcutaneous
Figure 1. Infectivity of cervical cancer cells by adenoviral vectors with fiber knob modifications and the effect of anti-inflammatory
reagents on transduction efficacy. (a–d) Cell lines were infected with Ad5luc1, Ad5/3luc1, and Ad5lucRGD. Luciferase activity is expressed as
relative light units (RLU) normalized for total protein concentration. (e–h) The effect of anti-inflammatory reagents on transduction efficacy of capsid
modified adenoviruses. Cells were infected in the presence of substances. The value without reagents was set at 1, and relative luciferase values are
shown. Each point represents the mean of three experiments6standard error. *P,0.05, **P,0.01, ***P,0.0001 versus Ad5luc1.
doi:10.1371/journal.pone.0002917.g001
Oncolytic Adenoviruses
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model, we used Hey ovarian cancer cells (Fig. 4j). Previous work
suggested that the viruses used here would replicate in Hey cells
[36,37]. Xenografts were treated with intratumoral injections of
36108 vp of viruses or no virus on days 1, 3 and 5. Mice received
intraperitoneal injections of PBS or dexamethasone daily, and
tumor growth was followed. Again, although there was a
suggestion of attenuation of virus replication (i.e. larger tumors),
dexamethasone had no significant effect on therapeutic efficacy of
analyzed viruses (P= from 0.8897 to 0.9441). The antitumor
efficacy of oncolytic adenoviruses continued to be significant
compared to mock-treatment (all P,0.0001).
The effect of dexamethasone on replication of Cox-2 and
VEGF promoter driven oncolytic adenoviruses and wild-
type adenovirus on cervical cancer cells in vitro
We analyzed the in vitro production of virions by RGDCRAD-
cox-2R, Ad5/3VEGF-E1 and wild-type adenovirus in SiHa cells
with and without dexamethasone treatment (Fig. 5a–c). Overall,
dexamethasone reduced the replication of analyzed viruses.
Replication of RGDCRADcox-2R was reduced 2-, 7-, and 10-
fold at 24, 60 and 96 h, respectively (Fig. 5a: P,0.0001 at 60 h). A
similar but weaker effect was seen with Ad5/3VEGF-E1 (Fig. 5b:
1.5 to 3.5-fold, P=0.0640 at 96 h). Replication of a wild-type virus
was significantly reduced at 96 h (Fig. 5c: 40-fold, P,0.0001).
The effect of dexamethasone on replication of Cox-2 and
VEGF promoter driven oncolytic adenoviruses and wild-
type adenovirus on cancer cells in vivo
Regulation of replication by dexamethasone in vivo was analyzed
with the subcutaneous human ovarian Hey adenocarcinoma
tumors treated with intratumoral injections on day 0. Half of the
mice received intraperitoneal injections of dexamethasone daily.
Tumors were analyzed on days 2 and 4. Although dexamethasone
reduced the replication of Ad5/3VEGF-E1 and wild-type virus at
early time point, the difference was not statistically significant
(Fig. 5d–f, all P=0.1283–0.6144).
Discussion
Because the primary adenovirus receptor may be frequently
absent or expressed aberrantly in advanced tumors [34], we first
analyzed in vitro transduction efficacy of fiber modified, infectivity
enhanced adenovirus vectors expressing the luciferase transgene
(Fig. 1). RGD-4C modification did not seem to be very effective in
increasing gene transfer, but the Ad3 receptor retargeted virus was
quite effective in three out of four cell lines (Fig.1a–d). Further, we
evaluated the effect of the anti-inflammatory reagents on
transduction efficacy, and found some increase in transgene
expression after treatment with dexamethasone on two out of four
cervical cancer cell lines (Fig.1 f,g) As a major determinant of the
efficacy of oncolytic adenoviruses is infectivity [34], we utilized
genetic fiber modifications for improving cell killing efficacy. We
evaluated the in vitro cytolytic potency of these oncolytic
adenoviruses in cervical cancer cell lines, and found correlation
Figure 2. Regulation of Cox-2 and VEGF promoter activity with
anti-inflammatory reagents. Monolayers were preincubated with
reagents, and C33A (a, b), SiHa (c, d), Caski (e, f) and HeLa (g, h) cells
were infected with 1 000 viral particles (vp)/cell of Ad5luc1 (with the
CMV controlling luciferase), Adcox-2Mluc or AdVEGFluc, and luciferase
expression was analyzed. Transgene expression level with Cox-2 and
VEGF promoters are compared to the CMV promoter (%). Each point
represents the mean of four experiments6standard error. *P,0.05,
**P,0.01, ***P,0.0001 versus no substance.
doi:10.1371/journal.pone.0002917.g002
Oncolytic Adenoviruses
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between oncolytic potency, gene delivery and promoter activity,
i.e. the stronger the promoter and higher the infectivity, the
stronger was the oncolytic potency (Fig. 3a–d).
More importantly, all the analyzed oncolytic adenoviruses had
statistically significant therapeutic efficacy in both local and
systemic treatment schemas of murine cervical cancer xenografts
Figure 3. Oncolytic adenoviruses display efficient killing of cervical cancer cells in vitro and in vivo. (a–d) Monolayers were infected with
RGDCRADcox-2R, Ad5/3VEGF-E1, Ad5-D24RGD, wild-type adenovirus and Ad5luc1 (E1-deleted control virus). Cell viability was measured with MTS
assay. The OD490 values of uninfected cells were set as 100%. Data is expressed as mean6standard error of quadruplicate experiments. (e–f) C33A
cells were injected subcutaneously into nude mice and advanced tumors were allowed to develop. The mice were treated either with (e) three
intratumoral injections of 16109 viral particles (vp) of Ad5luc1, wild-type virus or oncolytic adenoviruses on three consecutive days, or with (f) a single
intravenous injection of 161011 vp. *P,0.05, **P,0.01, ***P,0.0001 versus Ad5luc1. Bars indicate standard error.
doi:10.1371/journal.pone.0002917.g003
Oncolytic Adenoviruses
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Figure 4. Dexamethasone and sodium salicylate reduces oncolysis caused by Cox-2 and VEGF promoter driven oncolytic
adenoviruses and wild-type adenovirus in vitro but not in vivo. (a–h) Cell monolayers were preincubated with substances, and C33A (a–d) and
SiHa (e–h) cells were infected with Ad5luc1, wild-type virus, Ad5/3VEGF-E1 and RGDCRADcox-2R. Cell killing efficacy of replicating viruses was
reduced with dexamethasone (b, c, f–h) and sodium salicylate (c, f, g). To show the effect of the substances per se on cell survival, a second mock has
been added in panels a and e. The y-axis crossing point indicates cell viability without virus or substances, while the ‘‘0’’ to the right of it indicates cell
survival without virus but with substances. The in vivo effect of dexamethasone on therapeutic efficacy of oncolytic or wild-type adenoviruses. (i)
Subcutaneous C33A cervical cancer tumors were allowed to establish and mice were treated with a single intravenous injection of 161011 viral
particles (vp) of oncolytic viruses or no virus. In the RGDCRADcox-2R groups, 36108 vp were injected intratumorally on days 1, 3 and 5. In addition,
the mice received intraperitoneal dexamethasone or PBS. (j) Human ovarian cancer (Hey) tumors were established in nude mice, and treated with
intratumoral injections of 36108 vp of RGDCRADcox-2R, Ad5/3VEGF-E1, Ad5-D24RGD or no virus on days 1, 3 and 5. Mice received intraperitoneal
injections of PBS or dexamethasone daily. Bars indicate standard error. Despite a suggestive trend at some time points, dexamethasone did not affect
the growth of tumors significantly in overall analysis of either model. *P,0.05, **P,0.01, ***P,0.0001 versus no substance. Bars indicate standard
error.
doi:10.1371/journal.pone.0002917.g004
Oncolytic Adenoviruses
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(Fig. 3e, f). Some variation in efficacy was seen between in vitro and
in vivo results with some of the viruses. This may due to recent
discoveries suggesting that while gene delivery in vitro depends
mostly on primary adenovirus receptors, bioavailability issues
seem to dominate with regard to in vivo efficacy. For example, it is
increasingly accepted that while binding to CAR is an important
determinant of transduction in vitro, other regions of the fiber may
be even more relevant in vivo [38]. In parallel to previous findings
with other cell lines [37,39], wild type adenovirus was not effective
on C33A cells in vivo, despite activity in vitro. Although we assume
this relates to differences between in vitro and in vivo environments
(eg. stroma, vasculature, receptor expression), further work is
needed to clarify the issue.
When Cox-2 and VEGF promoter driven transgene expression
was evaluated, both promoters were found active in cervical
cancer cell lines. Overall, VEGF promoter activity was higher than
Cox-2 in all cell lines, and comparable to previous data [19].
Importantly, earlier studies have reported that normal liver cells
do not express VEGF [40]. Also Cox-2 levels seen in cervical
cancer cells were higher than what has been reported for the liver
previously [16]. Significant reduction of VEGF promoter
mediated luciferase expression was seen with sodium salicylate,
dexamethasone and salicylic acid (Fig. 2b, d). Sodium salicylate
also reduced Cox-2 promoter controlled transgene expression
(Fig. 2e).
When cell killing experiments were performed in the presence of
anti-inflammatory agents, dexamethasone and sodium salicylate
were effective in reducing oncolysis (Fig. 4). Interestingly, the effect
was not restricted to oncolytic adenoviruses, but also wild type
virus displayed weaker cytolysis when dexamethasone was present.
Thus, the effect might not be completely related to the promoter
controlling the replication, but a more general phenomenon in
viral replication might be also involved. One cause of reduced
replication might be down-regulation of the relevant receptors
required for infection. Previously, we and others have analyzed the
modulation of adenovirus primary receptor expression on the cell
surface by various substances including a number of chemother-
apeutics and anti-inflammatory reagents. We found no effect on
Figure 5. Dexamethasone reduces replication of oncolytic adenoviruses Ad5/3VEGF-E1, RGDCRADcox-2R and wild-type
adenovirus in vitro but not in vivo. (a–c) SiHa cervical cancer monolayers were infected with viruses alone (10 viral particle (vp)/cell) or in
combination with dexamethasone, and virus production was analyzed by plaque assay. Despite a clear trend at early time points, there was no
statistically significant effect of dexamethasone on in vivo replication due to larger variation in vivo (d–f). Human ovarian cancer tumors were
established in nude mice and treated with a single intratumoral injection of 36108 vp. Mice received intraperitoneal injections of dexamethasone or
PBS daily. Four tumors/group were harvested on days 2 and 4, and the amount of infectious particles was analyzed by TCID50. ***P,0.0001 versus
virus alone. N.A. = not analyzed. Bars indicate standard error.
doi:10.1371/journal.pone.0002917.g005
Oncolytic Adenoviruses
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receptor level, as assessed by flow cytometry analysis, after
dexamethasone treatment, while others detected a slight reduction
in the level of both primary receptor and avb integrins [41,42].
The effect of dexamethasone on the serotype 3 receptor had not
been studied, nor had the cell lines used here been studied before
with regard to the other relevant adenovirus receptors. We
therefore analyzed the effect of the substances on gene delivery
and found that in some cases luciferase expression was increased
(Fig. 1e–h). Thus, the reduced replication seen here was probably
not due to receptor downregulation.
Another mechanistic possibility might involve induction of Cox-2
by virus replication per se. With regard to herpes, cytomegalovirus,
and other DNA viruses, it has been demonstrated that virus infection
induces Cox-2 [43,44]. Further, the finding that inhibition of Cox-2
reduces replication of these viruses suggests that Cox-2 induction is
beneficial for virus propagation. These viruses may utilize the
anabolic effects of Cox-2 for optimization of their replication efficacy.
Preliminary data suggests that the same may also be true for
adenovirus, whichmight help explain why the oncolytic effect of wild-
type adenovirus was attenuated by dexamethasone [45].
Although oncolysis is likely to correlate with replication of the
virus, we investigated this separately. As expected, virus replication
was reduced with dexamethasone treatment in vitro (Fig. 5a–c). This
seems to support the theoretical assumption that oncolysis is tightly
linked with virus replication. As human adenoviruses do not
replicate productively in murine normal tissues [46], human
xenografts in mice were utilized for replication attenuation in vivo
studies. In these models, if replication and/or cell killing efficacy is
reduced in vivo with dexamethasone, tumors in mice treated with
virus and dexamethasone would be larger than virus only treated. In
both models studied, dexamethasone did not significantly reduce
the antitumor efficacy of the analyzed oncolytic adenoviruses,
despite a trend in that direction (Fig. 4i–j, all P$0.1654). Finally, we
analyzed the amount of infectious particles in subcutaneous tumors
with and without dexamethasone treatment (Fig. 5d–f). Despite a
trend prominent at early time points, no significant differences were
seen, which may be due to variation typical of in vivo experiments.
The most likely reason for the discrepancy between the observed
in vitro and in vivo effect of dexamethasone on the oncolytic potential
of the viruses may relate to the higher complexity of in vivo models.
These complexities were well demonstrated in a recent study where
an increase in VEGF levels in Cox-2 positive and Cox-2 negative
pancreatic cancer cells was seen after treatment with high
concentrations of Cox-2 inhibitors, suggesting that the relationship
between Cox-2 protein inhibition and VEGF or Cox-2 promoter
expression may not always be tightly linked [47]. Contrary to
expectations, both Cox-2 positive and negative in vitro models
displayed increased levels of VEGF following Cox-2 inhibition.
However, in the Cox-2 positive tumor in vivo model, non-malignant
cells expressed a markedly decreased level of murine VEGF leading
to reduced total VEGF and tumor angiogenesis and growth, while
Cox-2 negative tumors displayed increased tumor growth. These
results also suggest that the tumor stroma may have a major effect
on the expression of Cox-2 and related factors.
Another aspect relates to the non-linear relationship between
E1A levels and efficacy of virus replication. Classic studies suggest
that highly variable E1A levels allow effective replication without
direct correlation between E1A expression and virion production
[48]. Thus, is it quite possible, that even though E1A expression
was affected due to dexamethasone inhibiting the promoters, the
effect was not dramatic enough to be seen as a difference in tumor
growth curves. Dexamethasone regulates multiple components of
both innate and adaptive immunity. The nude mice used in the
study lack functional T cells, but possess normal B cells, NK cells,
macrophages etc. Innate immunity is important for clearance of
adenovirus and therefore it is possible that the effects of the drug
on virus and on the remaining immune system neutralized each
other, thus showing no significant differences.
Adenoviruses can cause severe toxicity in immunocompromized
individuals. Although clinical trials in cancer patients have
heretofore reported extremely good safety data [6,7], preclinical
work suggests that there is the potential for toxicity [49]. Further,
most oncolytic adenovirus trials completed have utilized early
generation viruses, which are rather attenuated in their replicative
potential. Thus, increasingly effective oncolytic adenoviruses could
result in more toxicity and therefore it would be useful if
replication could be abrogated if necessary. The data presented
here suggests that anti-inflammatory reagents dexamethasone and
sodium salicylate can reduce the activity of Cox-2 and VEGF
promoters. Further, this resulted in reduced replication and
oncolytic potential of the respective replicative viruses in vitro. The
effective doses were well within what would be predicted safe in
humans based on published trials [6,7,50,51].
Dexamethasone is routinely administered to cancer patients as
an anti-emetic or because of its anti-inflammatory, anabolic and
psycho-stimulating effects [52]. Dexamethasone use is particularly
prevalent in end-stage cancer patients, who could be candidate for
experimental approaches such as oncolytic viruses. This suggests
that it might be useful to address dexamethasone use in trial
protocols featuring agents that utilize the Cox-2 or VEGF
promoters. Moreover, if it is confirmed that dexamethasone
and/or other anti-inflammatories reduce adenovirus replication
and efficacy per se, this should be taken into account in all oncolytic
adenovirus trials. On the other hand, this phenomenon certainly
might be useful for intervention in case of side effects in trials.
Further, abrogation of replication could be useful in the rare cases
of dangerous adenovirus infections in immunosuppressed, trans-
plant and pediatric patients. Finally, the effect on anti-inflamma-
tories on Cox-2 promoter or protein levels, and their association
with virus replication, could help shed light on adenovirus biology,
and the interactions between human cells and adenoviruses.
Methods
Cell lines and agents
Caski, C33A, SiHa and HeLa cervical cancer and A549 lung
adenocarcinoma cell lines were obtained from ATCC (Manassas,
VA). 293 cells were purchased from Microbix (Toronto, Canada).
Ovarian adenocarcinoma Hey cells was obtained from Dr. Wolf
(M.D. Anderson Cancer Center, Houston, TX). Dexamethasone,
Sodium Salicylate, Salicylic Acid and TGF-b1 were purchased
from Sigma (St. Louis, MO). The concentrations used correspond
to achievable, bioactive and well tolerated concentrations in
human serum following treatment with the agents, as indicated by
the results of a comprehensive literature search.
Adenoviruses
The viruses utilized in the experiments are listed in Table 1. E1-
deleted viruses were propagated on 293 cells, while replicating
viruses were propagated on A549 cells. Viruses were purified on
cesium chloride gradients. The vp concentration was determined
at 260 nm, and plaque assay was performed to determine
infectious particles [37].
Adenovirus-mediated gene transfer assays
Cells were infected for 30 min, washed once, and complete
medium was added. After 24 h incubation, luciferase assay was
performed (Luciferase Assay System, Promega, Madison, WI).
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The protein concentration was determined using a Bio-Rad DC
protein assay kit (Bio-Rad, Hercules, CA). Background luciferase
activities were subtracted from the readings. In order to analyze
the effect of anti-inflammatory reagents on transduction efficacy,
Dexamethasone (392 ng/ml), Sodium Salicylate (160 mg/ml) and
Salicylic Acid (1.4 mg/ml) were added 18 h prior the infection,
and the infection and incubation were performed in the presence
of the substances. These doses did not cause toxicity to cells.
The effect of anti-inflammatory reagents on promoter
activity
Reagents were added 18 h prior the infection, and the infection
with Ad5luc1, Adcox-2Mluc or AdVEGFluc, and incubation were
performed in the presence of the substances. Luciferase expression
was analyzed as above. Transgene expression levels with Cox-2
and VEGF promoters are compared to CMV promoter, and
relative luciferase activities are shown. The results without
reagents were compared to the other groups. All comparisons
were conducted with a Student’s t-test with Satterthwaite’s
approximation for unequal variances if indicated (SAS v.9.1,
SAS Institute, Cary, NC). For all analyses a two-sided p value of
,0.05 was deemed statistically significant.
Cell killing assays
Cells in quadruplicate were infected with Ad5luc1, wild-type,
Ad5/3VEGF-E1, RGDCRADcox-2R and Ad5-D24RGD. There-
after, cells were incubated with complete growth medium. Cell
viability was measured using the MTS assay (Promega) when any
virus at 10 vp/cell displayed complete cell killing. The results with
Ad5luc1 and wild-type were compared to the other groups using
two-tailed t-test as above. The effect of anti-inflammatory agents
on cell killing efficacy was analyzed on C33A and SiHa cells.
Regulation of replication by dexamethasone in vitro
Cells were infected with viruses alone or in combination with
dexamethasone, and replication was analyzed after three freeze-
thaw cycles by plaque assay. The effects of dexamethasone was
analyzed using bootstrap multiple comparisons of means (PROC
MULTTEST SAS v9.1). The levels of viral replication were log
transformed for normality. A multiplicity adjusted bootstrap p
value of ,0.05 was deemed statistically significant.
In vivo cancer models
All animal protocols were reviewed and approved by the
Experimental Animal Committee of the University of Helsinki and
the Provincial Government of Southern Finland. In efficacy
experiment, mice were obtained from Charles River Laboratories
(Wilmington, MA) and subcutaneous tumors were established by
injecting 107 C33A cells into female nu/nu mice. 16109 vp of
Ad5luc1, wild-type, Ad5/3VEGF-E1, RGDCRADcox-2R, Ad5-
D24RGD, or no virus, were injected intratumorally on days 1, 2
and 3 (n=5 mice, 10 tumors/group). Another group of mice
received the virus intravenously as a single injection of 161011 vp
on day 1 (n=4 mice, 8 tumors). Tumor size was measured.
In the in vivo regulation assay, mice were obtained from Taconic
(Ejby, Denmark), subcutaneous C33A cell tumors were established
as above, and treated with a single intravenous injection of
161011 vp on day 1. To study the effect of a different route of
administration, 36108 vp were injected intratumorally on three
consecutive days in the RGDCRADcox-2R groups. Mice received
intraperitoneal injections of PBS or dexamethasone (50 mg) daily
(n=6 mice, 12 tumors/group). Tumor size was followed. 5/12
mice receiving intravenous Ad5/3VEGF-E1 treatment died within
12 h. Dexamethasone treatment did not affect toxicity. Livers
were harvested and fixed in buffered formalin. Histopathology did
not reveal any liver toxicity (data not shown).
Subcutaneous human ovarian cancer (Hey) tumors were
established in female NMRI CD-1 nude (n=5 mice, 10 tumors/
group), and treated with intratumoral injections of 36108 vp on
days 1, 3 and 5. Mice were treated with dexamethasone as above.
Regulation of replication by dexamethasone in vivo was analyzed
with the Hey cell tumors treated with a single intratumoral
injection. Half of the mice received dexamethasone. 4 tumors/
group were harvested on days 2 and 4, weighted, homogenized,
and the virions were released by three freeze-thaw cycles. The
amount of infectious particles was analyzed by TCID50. The
analysis of the tumor size data was performed using a repeated
measures growth model with PROC MIXED (SAS v.9.1), which
treated the within mouse effect of time as a continuous variable
and the treatment group as a fixed effect. The tumor size data was
log transformed. The effects of treatment group, time and the
interaction of treatment group and time were evaluated by F tests.
Baseline tumor size was included as a covariate in all models and
flank as a covariate. The a priori planned comparisons of
Table 1. Viruses used in the experiments.
Virus E1A Reporter Fiber Main receptor* Ratio{ Ref
Ad5luc1 deleted luciferase wild type CAR 5.4 [53]
Ad5/3luc1 deleted luciferase serotype 3 knob CD46 and unknown 5.0 [54]
Ad5lucRGD deleted luciferase RGD motif in HI-loop avb integrins and CAR 53 [55]
Adcox2Mluc deleted luciferase wild type CAR 60 [16]
AdVEGFluc deleted luciferase wild type CAR 67 [18]
Ad5-D24RGD 24 bp deletion - RGD motif in HI-loop avb integrins and CAR 39 [33]
RGDCRADcox-2R heterologous Cox-2 promoter
controlling E1A expression
- RGD motif in HI-loop avb integrins and CAR 8.5 [56]
Ad5/3VEGF-E1 heterologous VEGF promoter
controlling E1A expression
- serotype 3 knob CD46 and unknown 20 [24]
Ad300wt =wild
type human Ad5
wild type - wild type CAR 10 ATCC
*CAR = coxsackie-adenovirus receptor.
{ratio of viral particles (vp) to plaque forming units (pfu), a quality control measure and indicator of viral packaging efficacy.
doi:10.1371/journal.pone.0002917.t001
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differences in predicted treatment means were computed by t-
statistics at study’s end and averaged over all time points. Tukey-
Kramer adjustment was utilized to allow for multiple comparisons.
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